Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Azita Saleki is EVP, CHIEF OPERATIONS OFFICER at AbbVie. OQRO lists 11 transactions filed with the SEC under this name, the latest on Nov 18, 2026, each linked to the official Form 4.
EVP, CHIEF OPERATIONS OFFICER
Disclosures on record
11
Companies involved
2
AbbVieABBV
10 disclosures · Aug 2025 – Nov 2026 · 1 sold
Nov 16, 202624Kdisclosed Nov 18
DetailsOfficial recordNov 16, 202613Kdisclosed Nov 18
DetailsOfficial recordAs of the latest filing on , Azita Saleki reported holding 208,248 shares of AbbVie (ABBV), worth about $59.6M at the last close of $286 (Nov 18, 2026). Holdings are also on file at Entegris (ENTG); together they are worth about $63.4M.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| AbbVie ABBV | 208,248 | 208K direct | $286 | $59.6M | Nov 16, 2026 |
| Entegris ENTG | 26,383 | 26K direct | $144 | $3.79M | May 6, 2026 |
Is this Azita Saleki’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Nov 16, 202613Kdisclosed Nov 18
DetailsOfficial recordFeb 27, 202616Kdisclosed Mar 3
DetailsOfficial recordFeb 18, 202617Kdisclosed Feb 20
DetailsOfficial recordFeb 18, 20266,058disclosed Feb 20
DetailsOfficial recordFeb 18, 20267,074disclosed Feb 20
DetailsOfficial recordFeb 18, 20266,638disclosed Feb 20
DetailsOfficial recordFeb 18, 202620Kdisclosed Feb 20
DetailsOfficial recordAug 12, 2025Sold~$8.41Mdisclosed Aug 14
DetailsOfficial recordEntegrisENTG
May 6, 20261,412disclosed May 8
DetailsOfficial recordAzita Saleki has no open-market purchase on record since 2013. Sales in each of the last 3 years.
Azita Saleki reported 0 open-market purchases and 35 sales since 2013; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2025 | — | $8.41M1×1 trade |
| 2024 | — | $9.18M1×1 trade |
| 2023 | — | $9.45M5×5 trades |
| 2021 | — | $10.1M2×2 trades |
| 2020 | — | $2.16M2×2 trades |
| 2019 | — | $1.25M1×1 trade |
| 2018 | — | $157K1×1 trade |
| 2017 | — | $706K5×5 trades |
| 2016 | — | $98K1×1 trade |
| 2015 | — | $128K1×1 trade |
| 2014 | — | $151K8×8 trades |
| 2013 | — | $951K7×7 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Azita Saleki reported 0 open-market purchases and 35 sales here, 2013 to 2025.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
On the latest SEC Form 4, dated Nov 16, 2026, Azita Saleki reported holding 208,248 shares of AbbVie (ABBV). At the last close of $286 on Nov 18, 2026, that is about $59.6M. This is the stake disclosed in filings, not a net worth.
No public filing gives Azita Saleki's net worth. What SEC Form 4 shows is the stock stake: 208,248 shares of AbbVie (ABBV), about $59.6M at the last close, plus holdings in 1 other company, about $63.4M in all. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
Azita Saleki has no open-market purchase on record since 2013. Sales in each of the last 3 years.
In SEC filings since 2013: no open-market purchase is on record; the latest open-market sale is from 2025.
AbbVie (ABBV), from 2013 to 2025: 0 purchases and 35 sales.